Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0
|
作者：
Yang, J. [1 ]
Cheng, Y. [2 ]
Murakami, H. [3 ]
Yang, P-C. [1 ]
He, J. [4 ]
Nakagawa, K. [5 ]
Kang, J. H. [6 ]
Kim, J-H. [7 ]
Hozak, R. [8 ]
Nguyen, T. [9 ]
Wang, X. [10 ]
Enatsu, S. [11 ]
Puri, T. [12 ]
Orlando, M. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan
[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China
[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea
[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA
[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China
[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan
[12] Eli Lilly & Co, Med Affairs, Gurgaon, India
[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1240P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
    Yang, James Chih-Hsin
    Kang, Jin Hyoung
    Mok, Tony
    Ahn, Myung-Ju
    Srimuninnimit, Vichien
    Lin, Chia-Chi
    Kim, Dong-Wan
    Tsai, Chun-Ming
    Barraclough, Helen
    Altug, Sedat
    Orlando, Mauro
    Park, Keunchil
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2219 - 2230
  • [42] Tumor epidermal growth factor receptor (EGFR) expression as a predictive biomarker of survival in FLEX study patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy plus cetuximab as first-line therapy
    von Pawel, J.
    Eberhardt, W. E. E.
    Reck, M.
    Eschbach, C.
    Fischer, J. R.
    Schuette, W.
    Bohnet, S.
    Heeger, S.
    Schumacher, K. -M.
    von Heydebreck, A.
    Pirker, R.
    ONKOLOGIE, 2011, 34 : 121 - 121
  • [43] Gefitinib plus Fuzheng Kang'ai Formula in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial
    Yang Xiao-bing
    Chai Xiao-shu
    Wu Wan-yin
    Long Shun-qin
    Deng Hong
    Pan Zong-qi
    He Wen-feng
    Zhou Yu-shu
    Liao Gui-ya
    Xiao Shu-jing
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2018, 24 (10) : 734 - 740
  • [44] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
    Eric Nadler
    Melissa Pavilack
    Janet L. Espirito
    Jamyia Clark
    Ancilla Fernandes
    Advances in Therapy, 2020, 37 : 946 - 954
  • [45] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
    Nadler, Eric
    Pavilack, Melissa
    Espirito, Janet L.
    Clark, Jamyia
    Fernandes, Ancilla
    ADVANCES IN THERAPY, 2020, 37 (02) : 946 - 954
  • [46] First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study)
    Minegishi, Y.
    Maemondo, M.
    Okinaga, S.
    Morikawa, N.
    Inoue, A.
    Kobayashi, K.
    Harada, M.
    Hagiwara, K.
    Nukiwa, T.
    Gemma, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
    Miyauchi, Eisaku
    Inoue, Akira
    Kobayashi, Kunihiko
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Saijo, Yasuo
    Yoshizawa, Hirohisa
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 670 - 676
  • [48] Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)
    Mitsudomi, Tetsuya
    Morita, Satoshi
    Yatabe, Yasushi
    Negoro, Shunichi
    Okamoto, Isamu
    Seto, Takashi
    Satouchi, Miyako
    Tada, Hirohito
    Hirashima, Tomonori
    Asami, Kazuhiro
    Katakami, Nobuyuki
    Takada, Minoru
    Yoshioka, Hiroshige
    Shibata, Kazuhiko
    Kudoh, Shinzoh
    Shimizu, Eiji
    Saito, Hiroshi
    Toyooka, Shinichi
    Nakagawa, Kazuhiko
    Fukuoka, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
    Ke, E-E
    Wu, Yi-Long
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 256 - 264
  • [50] Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation
    Kanda, Shintaro
    Ohe, Yuichiro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Kubota, Kaoru
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345